Doug Fisher

Dr Doug Fisher


Dr. Doug Fisher joined InterWest's life sciences team in 2009, focusing on biopharmaceutical and diagnostics investments. He is a board member of Cardiac Dimensions and Gynesonics. Dr. Fisher also is actively involved in InterWest's investments in Integrated Diagnostics and Invuity.
Prior to joining InterWest, Dr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including: Pearl Therapeutics, Access Closure, and GluMetrics. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in three new disease areas for Remicade.
Dr. Fisher received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.


Associate (Menlo Park) (past)
(Menlo Park) (current)